Eight isolates had three codon changes (8/56: 14%), and twenty-one isolates had two codon Nintedanib chemical structure changes (21/56: 38%) (Table 1). The isolates with multiple codon changes generally included changes at codon 533 (26/30: 87%). The remaining isolates (26) had only one codon change (26/56: 46%), most commonly at codon 531 (22/26: 85%) (Table 1). Changes to codons 531 and 533 occurred in 53 patients (53/56: 95%). The mutation S531 L (TCG/TTG) was by far the most frequent (35 patients: 35/56: 63%), followed by L533R (CTG/CGT) (12 patients: 12/56: 21%), L533P (CTG/CCG) (7 patients: 7/56: 13%), L533R

(CTG/CGG) (5 patients: 5/56: 9%) and H526D (CAC/GAC) (4 patients: 4/56: 7%) (Table 2). Based on the information provided by the TB drug resistance mutation database [23], which lists all published mutations that have been associated with rifampicin resistance, 15 of the 30 different missense codon changes obtained (excluding silent codon changes) represent novel codon changes (50%). Most of the novel SB203580 price changes were located in codon 533. Novel codon changes represent 31 of the total 92 codon changes (34%) and were identified in 30 of the 56 patients (54%) (Table 2). The new codon changes at positions 529 and 532 indicate mutations at new locations. The codon changes included (43) different base pair changes (nucleotide position or base) resulting in a total of 134 bp changes (63 transitions and 71 transversions).

Of the 97 codon changes, 68 (70%) included a single base pair change, 22 (23%) included two, and 7 (7%) included three base pair changes. It appears that 18 codon changes involved 2 bp inversions (Table 1). Most of the missense codon changes represented

learn more non-conservative amino acid replacements. The most frequent codon changes at position 531 involve a switch from a polar to a hydrophobic residue (S/L, I), while the changes at position 533 resulted in a switch from a hydrophobic to a charged residue (L/R). Several of the codon changes involved mutations to proline, a known secondary structure disrupter (Table 2). The fact that all isolates with phenotypic resistance to rifampicin used in this study exhibited amino acid changes in the RRDR region demonstrates the importance of the RRDR hotspot region in the resistance of clinical TB isolates in Syria. Several studies have indicated that this region is responsible for 90–95% of RIF-resistance cases [24]. However, many new mutations were identified in this study, and some were found at new locations within the RRDR. Notably, the vast majority of patients (95%) had mutations in codons 531 and/or 533. This could greatly reduce the expense and complexity of future early detection efforts in the local patient pool. Earlier studies [24] have asserted the importance of codon positions 526 and 531 to the observed resistance. This is true also in neighboring countries, such as Turkey.